References

1. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020 2020/05/20/.

2. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv. 2020:2020.04.11.20062349.

3. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv. 2020:2020.04.17.20061440.

4. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. The Journal of Infectious Diseases. 2020;221(11):1762-9.

5. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. The Journal of Infectious Diseases. 2020.

6. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation. 2020 04/13/;130(5).

7. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv. 2020:2020.03.05.20030502.

8. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv. 2020:2020.03.02.20030189.

9. OKBA NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020:2020.03.18.20038059.

10. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. medRxiv. 2020:2020.03.16.20035014.

11. Long Q-x, Deng H-j, Chen J, Hu J, Liu B-z, Liao P, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv. 2020:2020.03.18.20038018.

12. Wan WY, Lim SH, Seng EH. Cross-reaction of sera from COVID-19 patients with SARS-CoV assays. medRxiv. 2020:2020.03.17.20034454.

13. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. 2020.

14. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. The Journal of general virology. 2020 May 20.

15. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. The Journal of infection. 2020 Mar 21.

16. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. JAMA. 2020.

17. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerging infectious diseases. 2007;13(10):1562-4.

18. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435-46.

19. Neil M Ferguson, Daniel Laydon, Gemma Nedjati-Gilani, Natsuko Imai, Kylie Ainslie, Marc Baguelin, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand: Imperial College; 2020 [updated 16 March, 2020; cited 2020 23 March, 2020]. Available from: https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf.

20. Edridge AW, Kaczorowska JM, Hoste AC, Bakker M, Klein M, Jebbink MF, et al. Human coronavirus reinfection dynamics: lessons for SARS-CoV-2. medRxiv. 2020:2020.05.11.20086439.

21. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020 May 22;368(6493):860-8.

22. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020:2020.03.13.990226.

23. Medizinische Universität Innsbruck. Ischgl-Studie: 42,4 Prozent sind Antikörper-positiv [Internet]. Innsbruck: Universität Innsbruck; 2020 [cited 29 June 2020]. Available from: https://www.i-med.ac.at/mypoint/news/746359.html.

24. Bundesministerium für Bildung WuF. Österreichische COVID-19 Studie Vienna: Bundesministerium für Bildung, Wissenschaft und Forschung; 2020 [10 June 2020]. Available from: https://www.bmbwf.gv.at/Themen/Forschung/Aktuelles/COVID-19-Studie.html.

25. Herzog S, De Bie J, Abrams S, Wouters I, Ekinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples. medRxiv. 2020:2020.06.08.20125179.

26. Tsaneva-Damyanova D. SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria. Biotechnology & Biotechnological Equipment. 2020 2020/01/01;34(1):441-6.

27. Institute of Health Information and Statistics of the Czech Republic (UZIS). Studie kolektivní imunity SARS-CoV-2-CZ-Preval Praha: UZIS; 2020 [8 June 2020]. Available from: https://covid-imunita.uzis.cz/index.php?pg=vystupy-a-vysledky.

28. Jerkovic I, Ljubic T, Basic Z, Kruzic I, Kunac N, Bezic J, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia. medRxiv. 2020:2020.05.11.20095158.

29. Bloddonor. Coronavirus: Som bloddonor hjælper du nu med at afdække det danske mørketal Taastrup: Bloddonor; 2020 [8 June 2020]. Available from: https://bloddonor.dk/coronavirus/#.

30. National Institute for Health and Welfare of Finland (Institutet för hälsa och välfärd - THL). Koronaepidemian väestöserologiatutkimuksen viikkoraportti Helsinki: THL; 2020 [8 June 2020]. Available from: https://www.thl.fi/roko/cov-vaestoserologia/sero_report_weekly.html.

31. Grzelak L, Temmam S, Planchais C, Demeret C, Huon C, Guivel F, et al. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors. medRxiv. 2020:2020.04.21.20068858.

32. Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. medRxiv. 2020:2020.05.11.20092916.

33. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Research Square. 2020;In Review.

34. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 16 de abril de 2020. [21 April, 2020]. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2023.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2016%20de%20abril%20de%202020.pdf.

35. Brotons C, Serrano J, Fernandez D, Garcia-Ramos C, Ichazo B, Lemaire J, et al. Seroprevalence against COVID-19 and follow-up of suspected cases in primary health care in Spain. medRxiv. 2020:2020.06.13.20130575.

36. Folkhälsomyndigheten (FHM). Första resultaten från pågående undersökning av antikroppar för covid-19-virus Stockholm: FHM; 2020 [cited 8 June 2020]. Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus/.

37. Folkhälsomyndigheten (FHM). Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 2) [Internet]. Stockholm: Folkhälsomyndigheten; 2020 [updated 18 June 2020; cited 29 June 2020]. Available from: https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf.

38. Folkhälsomyndigheten (FHM). Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare [Internet]. Stockholm: Folkhälsomyndigheten; 2020 [updated 18 June 2020; cited 29 June 2020]. Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/juni/forsta-resultaten-om-antikroppar-efter-genomgangen-covid-19-hos-blodgivare/.

39. Eliasson M, Jatko P, Lundqvist R, Nystedt A, Arbetsgruppen för covid-19-epidemiologi. Förekomst av antikroppar mot covid-19 i Norrbottens befolkning maj 2020 [Internet]. Luleå: Regionen Norrbotten; 2020 [cited 29 June 2020]. Available from: https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20f%C3%B6rekomst%20av%20antikroppar/F%C3%B6rekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf.

40. Public Health England (PHE). Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report London: PHE; 2020 [8 June 2020]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/889981/Weekly_COVID19_Epidemiological_Summary_w23.pdf.

41. Thompson C, Grayson N, Paton R, Lourenço J, Penman B, Lee LN, et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure. medRxiv. 2020:2020.04.13.20060467.